^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BMS-986218

    i
    Other names: BMS-986218, CTLA-4-NF, BMS 986218
    Associations

    News

    Trials
    Company:
    BMS
    Drug class:
    CTLA4 inhibitor
    Related drugs:
    Associations

    News

    Trials
    3d
    First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=512, Terminated, Bristol-Myers Squibb | N=390 --> 512 | Active, not recruiting --> Terminated; Business Objectives have changed.
    Enrollment change • Trial termination • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • BMS-986218
    4ms
    First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=390, Active, not recruiting, Bristol-Myers Squibb | Trial primary completion date: Dec 2023 --> Apr 2024
    Trial primary completion date • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • BMS-986218
    5ms
    A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=10, Completed, Bristol-Myers Squibb | Recruiting --> Completed | N=204 --> 10
    Trial completion • Enrollment change • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • docetaxel • BMS-986218
    5ms
    A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=204, Recruiting, Bristol-Myers Squibb | Trial completion date: Feb 2026 --> Dec 2023 | Trial primary completion date: Feb 2026 --> Dec 2023
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • docetaxel • BMS-986218
    1year
    First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=390, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • BMS-986218
    almost4years
    [VIRTUAL] Preclinical characterization of BMS-986218, a novel nonfucosylated anti‒CTLA-4 antibody designed to enhance antitumor activity (AACR-II 2020)
    Background: Blockade of the CTLA-4 pathway with ipilimumab (IPI) as monotherapy or in combination with nivolumab (anti–PD-1) is an effective treatment for a variety of cancers. Nonfucosylation of an anti–CTLA-4 antibody increased binding affinity to CD16, induced depletion of Tregs while increasing T-effector cells in mouse tumors, and enhanced tumor growth inhibition in a dose-dependent manner, thus demonstrating improved ADCC compared with IPI. An ongoing phase 1/2 study is evaluating the safety and antitumor activity of anti–CTLA-4 NF alone and in combination with nivolumab (NCT03110107) in patients with advanced solid cancers.
    Preclinical
    |
    IL2 (Interleukin 2) • FOXP3 (Forkhead Box P3)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • BMS-986218